This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
IDNT is the acronym used for an ancillary study titled “Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT.” The registry identifies cardiovascular diseases, atherosclerosis, heart diseases, non-insulin-dependent diabetes mellitus, hypertension, and diabetes mellitus among the study conditions.
| Feature | IDNT |
|---|---|
| Study acronym | IDNT |
| Registry identifier | NCT00021918 |
| Official study title | Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT |
| Status | COMPLETED |
| Start date | 2001-04 |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Enrollment | Not reported in the registry record |
2. Clinical Question
The registry identifies the study as an ancillary investigation of serum total homocysteine and C-reactive protein associated with IDNT. The listed conditions span cardiovascular and metabolic disease, including cardiovascular diseases, atherosclerosis, heart diseases, non-insulin-dependent diabetes mellitus, hypertension, and diabetes mellitus.
Study focus
Serum total homocysteine and C-reactive protein are the biomarkers named in the registered study title.
Study context
The study is identified as ancillary to IDNT rather than as a standalone therapeutic trial in the registry title.
Clinical conditions
The registry lists cardiovascular diseases, atherosclerosis, heart diseases, non-insulin-dependent diabetes mellitus, hypertension, and diabetes mellitus.
Primary statistical question
The registry does not list a registered primary endpoint, so it does not establish a primary endpoint-specific hypothesis or estimand.
3. Trial Design
The available registry information identifies IDNT as an ancillary study. The registry lists the study status as completed and gives a start date of 2001-04. It does not provide a registered primary endpoint or posted statistical analysis.
Serum total homocysteine
- Named directly in the registered study title
- Analyzed in the context of the IDNT ancillary study
C-reactive protein
- Named directly in the registered study title
- Analyzed in the context of the IDNT ancillary study
4. Registered Endpoints
The ClinicalTrials.gov record does not list any registered primary endpoints for NCT00021918. Consequently, there is no registry-defined primary outcome, endpoint time frame, event definition, or prespecified primary comparison available to summarize.
5. Planned Analysis
No primary endpoint-specific statistical analysis is specified in the registry because no registered primary endpoints are listed. No formal statistical analyses are posted on ClinicalTrials.gov for this study.
How biomarker endpoints of this type are typically analysed
For an ancillary biomarker investigation involving continuous measurements such as serum total homocysteine or C-reactive protein, statistical analysis ordinarily begins by defining the biomarker measurement, the comparison of interest, and the analysis population. The appropriate method depends on the scientific question and the distribution of the measurements.
| Statistical question | Common analytical approach | Key consideration |
|---|---|---|
| How are biomarker values distributed? | Descriptive statistics, histograms, quantiles, and measures of central tendency and dispersion | Biomarker distributions may be asymmetric, so the mean alone may not adequately describe the data. |
| Do two groups differ in a continuous biomarker? | Two-sample comparison or regression-based analysis | The choice depends on the design, scale, distribution, and covariates. |
| Does a biomarker differ after accounting for baseline characteristics? | Linear regression or ANCOVA-type modeling | Adjustment variables should be selected based on the study design and scientific rationale. |
| Is the biomarker strongly skewed? | Transformation or an analysis appropriate for the observed distribution | The transformation and interpretation should be prespecified or clearly documented. |
| Is the question about association with a clinical outcome? | Regression models appropriate to the outcome, such as logistic or time-to-event models | Association does not by itself establish that a biomarker causes the outcome. |
For C-reactive protein in particular, distributional assessment can be important because inflammatory biomarkers may be substantially asymmetric. A log-scale analysis can sometimes provide a more stable representation when the scientific question concerns relative rather than absolute differences. The choice should follow the actual measurement distribution and prespecified scientific objective rather than being selected after examining which transformation produces the most favorable result.
For total homocysteine, the same general principle applies: the statistical scale should match the distribution and the question being asked. A mean difference, median difference, ratio, or regression coefficient answers a different question, so these quantities should not be treated as interchangeable.
6. Statistical Methodology
Descriptive analysis comes first
When the outcome is a continuous biomarker, descriptive analysis establishes the scale and distribution before formal modeling. Useful summaries can include the mean and standard deviation when appropriate, together with the median and interquartile range when the distribution is asymmetric.
In a simple linear model, Y represents a continuous biomarker and X represents the comparison or predictor of interest. The coefficient β1 describes the modeled change in the biomarker associated with a one-unit change in X, conditional on the model specification.
Mean difference
A mean difference compares the average biomarker level between two groups. It is directly interpretable on the original measurement scale, but it can be sensitive to extreme observations when the distribution is highly skewed.
A negative value indicates a lower estimated mean in group 1 than in group 0; a positive value indicates a higher estimated mean.
Regression adjustment
When baseline characteristics are relevant to the biomarker comparison, regression can estimate an adjusted association while accounting for specified covariates. This is particularly useful when the scientific question is not simply whether two raw group means differ, but whether a biomarker remains associated with an exposure or characteristic after accounting for other measured variables.
Log-transformed biomarkers
When a biomarker has a right-skewed distribution, analyzing its logarithm can make model assumptions more plausible and can shift the interpretation from an absolute difference toward a relative comparison. Back-transformation can then express the modeled contrast on the original scale.
Exponentiating a coefficient from a log-scale model gives a multiplicative interpretation. For example, an exponentiated coefficient of 1.10 corresponds to an estimated 10% higher geometric mean associated with the modeled comparison, all else equal.
Association is not causation
An ancillary biomarker analysis can identify statistical associations between biomarker measurements and clinical characteristics or outcomes. Such an association does not by itself establish a causal pathway. Causal interpretation requires appropriate design assumptions, temporal ordering, control of relevant confounding, and a clearly specified causal estimand.
7. Statistical Methods Explained
Why start with the distribution of the biomarker?
A continuous biomarker can have a roughly symmetric distribution or can be concentrated near one end of its possible range. Distributional shape affects whether a mean and standard deviation provide an adequate summary and whether a standard linear model is a reasonable description of the data.
What does a mean difference tell us?
A mean difference describes the difference in average biomarker concentration between two defined groups. It is an absolute measure on the biomarker's original scale. It does not automatically describe the difference in medians, the percentage change, or the relationship between the biomarker and a clinical event.
Why might a log transformation be considered?
A log transformation can reduce right skew and make multiplicative relationships easier to model. On the log scale, additive model coefficients correspond after exponentiation to ratios on the original scale. This can be useful when relative differences are more scientifically meaningful than absolute differences.
What is ANCOVA doing in a biomarker analysis?
ANCOVA combines a group comparison with regression adjustment for specified covariates. Conceptually, it asks whether groups differ in their expected biomarker value after accounting for the covariates included in the model. The validity of that interpretation depends on the model specification and its assumptions.
What does a confidence interval tell us?
A confidence interval quantifies statistical uncertainty around an estimated parameter under the specified model and sampling framework. A narrow interval indicates greater precision than a wide interval, but neither width nor location of the interval establishes clinical importance by itself.
Why does a p-value not measure effect size?
A p-value addresses evidence against a specified null hypothesis under the statistical model. It does not tell us how large or clinically important an observed association is. Effect size, confidence interval, measurement scale, and clinical context are needed to interpret magnitude.
8. Multiplicity and Multiple Biomarkers
The study title identifies two biomarkers: serum total homocysteine and C-reactive protein. However, the registry does not provide a registered endpoint hierarchy or a posted multiplicity strategy.
When several biomarkers, outcomes, subgroups, or statistical contrasts are examined, the probability of observing at least one apparently unusual result can increase simply because multiple opportunities for a finding have been created. A confirmatory analysis therefore benefits from prespecifying which hypotheses are primary and how multiplicity will be controlled.
Two biomarkers, different questions
Total homocysteine and C-reactive protein are distinct measurements. A finding for one biomarker does not automatically establish the same finding for the other.
Multiple comparisons
Testing many associations can generate apparently notable results by chance. The inferential framework should account for the number and relationship of hypotheses being tested.
Because no statistical analysis plan is posted in the registry record, the specific multiplicity procedure used for IDNT cannot be identified from ClinicalTrials.gov.
9. Missing Data and Measurement Issues
Biomarker analyses have a distinct missing-data problem: a participant may have clinical information but lack a measurement for one or both biomarkers. The statistical consequences depend on why the measurement is missing and on how the analysis handles incomplete observations.
| Issue | Statistical concern |
|---|---|
| Missing biomarker measurement | The analyzed sample may differ from the broader study population if biomarker availability is related to participant characteristics. |
| Different availability of the two biomarkers | The effective populations for total homocysteine and C-reactive protein may differ. |
| Extreme biomarker values | Outlying measurements can have disproportionate influence on means and regression estimates. |
| Assay or measurement variability | Measurement error can attenuate associations and increase uncertainty. |
| Post hoc exclusions | Removing observations after examining results can change the target population and introduce selection concerns. |
The registry record does not describe a missing-data or imputation strategy for the ancillary study. Consequently, the appropriate approach cannot be attributed to the IDNT record itself.
10. Interpretation of Biomarker Effect Estimates
An estimated difference in mean biomarker concentration describes the absolute separation between two modeled means. Its interpretation depends on the units and clinical meaning of the biomarker.
A ratio of geometric means describes a multiplicative difference. A value below 1 represents a lower geometric mean in the numerator group, while a value above 1 represents a higher geometric mean.
A regression coefficient describes the modeled change in the outcome associated with the corresponding predictor, conditional on the variables included in the model. It should not be interpreted outside the scale and specification of the fitted model.
11. What the Registry Establishes
| Item | Registry information |
|---|---|
| Study identifier | NCT00021918 |
| Acronym | IDNT |
| Study title | Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT |
| Status | COMPLETED |
| Start date | 2001-04 |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Conditions | Cardiovascular Diseases; Atherosclerosis; Heart Diseases; Diabetes Mellitus, Non-insulin Dependent; Hypertension; Diabetes Mellitus |
| Enrollment | Not reported |
| Registered primary endpoints | None listed |
| Posted statistical analyses | None listed |
12. Limitations
- No registered primary endpoint: the ClinicalTrials.gov record does not identify a primary endpoint or its time frame, so a confirmatory endpoint-specific analysis cannot be characterized from the registry.
- No posted statistical analyses: the registry contains no posted formal statistical analyses for this study.
- Enrollment not reported: the available registry record does not provide a study enrollment number.
- Ancillary-study context: the study is identified as ancillary to IDNT, so its scientific question should be distinguished from the primary question of the parent study.
- Biomarker interpretation: biomarker associations are sensitive to measurement quality, distributional assumptions, missingness, confounding, and the choice of statistical scale.
- Multiplicity: two named biomarkers create more than one potential inferential target, but the registry does not describe a multiplicity strategy.
- Clinical interpretation: a statistically detectable biomarker difference is not automatically a clinically meaningful difference, and an association does not establish causation.
13. Why This Trial Matters Statistically
IDNT is useful as a teaching case because it illustrates an important distinction between what a clinical trial registry records and what a complete statistical analysis requires. The registry identifies a focused ancillary biomarker question but does not supply the endpoint hierarchy, sample size, or formal analysis plan needed to reconstruct a confirmatory results analysis.
| Statistical concept | How it applies to IDNT |
|---|---|
| Ancillary analysis | The study is identified as ancillary to IDNT rather than as a standalone therapeutic trial. |
| Continuous outcomes | Serum total homocysteine and C-reactive protein are biomarker measurements that would generally be analyzed as quantitative variables. |
| Distributional assessment | Understanding biomarker distributions is important before selecting a statistical scale or model. |
| Regression adjustment | Regression can be used when the scientific question requires adjustment for prespecified covariates. |
| Transformation | A log scale may be useful for strongly right-skewed biomarkers when a multiplicative interpretation is scientifically appropriate. |
| Confidence intervals | Intervals quantify uncertainty around estimated biomarker differences or associations. |
| Multiplicity | Multiple biomarkers or multiple hypotheses require an explicitly defined inferential strategy. |
| Missing data | Availability of biomarker measurements can affect the population contributing to an analysis. |
| Association vs causation | Statistical association between a biomarker and another characteristic does not by itself establish a causal relationship. |
14. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
A biomarker analysis requires a defined estimand, analysis population, statistical model, uncertainty measure, and inferential framework. The registry does not specify these elements for a primary endpoint in NCT00021918.
Clinical interpretation
The study title places total homocysteine and C-reactive protein within cardiovascular and metabolic disease research. The clinical meaning of any biomarker association would depend on its magnitude, uncertainty, biological context, and relationship to clinically meaningful outcomes.
15. Record Summary
IDNT (NCT00021918) is a completed ancillary study titled “Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT.” The registry identifies the National Heart, Lung, and Blood Institute as the lead sponsor and NIH as the sponsor type, with a start date of 2001-04. The listed conditions include cardiovascular diseases, atherosclerosis, heart diseases, non-insulin-dependent diabetes mellitus, hypertension, and diabetes mellitus.
From a statistical perspective, the most important feature of the record is the limited amount of registered analysis information: no registered primary endpoints and no posted statistical analyses are listed. That makes IDNT a useful example of why biomarker research should be interpreted through an explicitly defined estimand, endpoint definition, analysis population, distributional assessment, model, uncertainty interval, and multiplicity strategy rather than through a biomarker name alone.
16. Sources
- ClinicalTrials.gov: NCT00021918 — IDNT: Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT.
Continue through the Clinical Biostats knowledge graph
Explore statistical tutorials, calculators, and additional clinical-trial analyses covering study design, endpoint definition, regression, biomarkers, and clinical-trial methodology.